Table 1.

Summary of clinical features and glucocerebrosidase enzyme activity in Parkinson’s disease and GBA1 mutation groups

					p value
	GD1 PD (n=3)	GBA1 PD (n=15)	IPD (n=8)	Non-PD carriers (n=4)	GBA1 PD vs. IPD	GBA1 PD vs. non-PD carriers	IPD vs. non-PD carriers
Women, % (n)	66.7 (2)	40.0 (6)	25.0 (2)	50.0 (2)	0.66	0.57	0.55
Age, years	58.0 (7.0)	67.0 (10.0)	63.5 (11.5)	64.0 (4.5)	0.92	0.76	0.67
Onset age, years	53.0 (10.0)	59.0 (17.0)	57.5 (5.5)	---	0.90	---	---
Duration, years	5.0 (3.0)	10.5 (8.0)	5.0 (8.0)	---	0.67	---	---
H&Y stage	2.0 (1.5)	2.0 (1.0)	2.0 (0.0)	---	0.17	---	---
Activity a	6.4 (5.7)	16.0 (7.0)	28.5 (15.0)	25.5 (2.5)	0.01	0.04	0.73

Data are presented as median (interquartile range) unless otherwise indicated. GBA1 PD = monoallelic GBA1 mutation carriers with Parkinson’s disease, GD1 PD = biallelic GBA1 mutation carriers with Parkinson’s disease, H&Y = Hoehn and Yahr, IPD = idiopathic Parkinson’s disease participants without GBA1 mutations, Non-PD carriers: GBA1 mutation carriers without Parkinson’s disease, vs. = versus.

^anmol/mg protein/hour.